HRTX

Cinvanti

Nausea Associated With Chemo

Quarterly sales (approved)

Exp Date

August 5, 2020 (Est)

Amp Volatility Score

Catalyst Info & Data Links

TITLE: Quartrly Sales for Cinvanti (FDA-approved drug)


WHAT IS THE CATALYST EVENT?

  • Approved Quarterly Sales


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • August 3, 2020 (Est)


PRIOR DATA

PRESS RELEASE




POSTERS





PUBLICATIONS









COMPETITORS


Neurokinin-1 (NK-1) receptor antagonist:

MARKET

  • ~4 million people per year receiving chemotherapy

  • ~CINV affects 70-80% of patients undergoing chemotherapy

  • See details

MECHANISM OF ACTION/ RATIONALE

  • Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors. Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupies brain NK1 receptors. Animal and human studies show that aprepitant augments the antiemetic activity of the 5-HT3-receptor antagonist ondansetron and the corticosteroid dexamethasone and inhibits both the acute and delayed phases of cisplatin-induced emesis 

  • Source - FDA Label (section 12.1)

Updated by HC

HRTX, Civanti, Heron, CINV, Chemotherapy-induced nausea and vomiting

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

HRTX CRL for HTX-011...

Heron Therapeutics received a Complete Response Letter from the U.S. FDA for the NDA for HTX-011 which is used for post-operative pain. The FDA stated that the CRL was given out because of a need for ...

HRTX - bear or bull? Our take ...

Heron has an upcoming PDUFA date for its longer acting post-op pain medicine, HTX-011. This is the second time around for HTX-011 as the first time unfortunately resulted in a CRL. See our article (HE...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon